Peer review reports
From: Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
Original Submission |
25 Jun 2022 |
Submitted |
Original manuscript
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
11 Oct 2022 |
Reviewed |
Reviewer Report
|
2 Nov 2022 |
Reviewed |
Reviewer Report - Lynn Mcroy
|
26 Nov 2022 |
Author responded |
Author comments - Jin Yang
|
Resubmission - Version 4 |
26 Nov 2022 |
Submitted |
Manuscript version 4
|
29 Nov 2022 |
Author responded |
Author comments - Jin Yang
|
Resubmission - Version 5 |
29 Nov 2022 |
Submitted |
Manuscript version 5
|
4 Dec 2022 |
Reviewed |
Reviewer Report
|
Resubmission - Version 6 |
|
Submitted |
Manuscript version 6
|
Publishing |
19 Jan 2023 |
Editorially accepted |
|
30 Jan 2023 |
Article published |
10.1186/s12885-023-10568-0
|
Learn about peer review